Breast Cancer Clinical Trial
— COG STIM 2Official title:
Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer: a Multicenter Randomized Controlled Trial
Verified date | August 2023 |
Source | Centre Francois Baclesse |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigator propose the first French randomized comparative study to assess the efficacy of a remotely supervised online cognitive stimulation program, compared to an unsupervised online cognitive exercise intervention, in reducing cognitive complaints in localized breast cancer patients after adjuvant chemotherapy. Previous randomized studies have confirmed the effectiveness of online cognitive stimulation programs compared to standard care. The study seeks to determine the added value of remote supervision by a neuropsychologist. The control group will have access to the same online cognitive exercises as the experimental group but without supervision. Investigator has chosen not to include a wait-list group as it would be unethical to deny patients with cognitive complaints the opportunity to participate in an intervention expected to benefit them. The secondary objective is to evaluate the benefit of the supervised digitalized cognitive intervention on objective cognitive impairment. The research hypothesis is that incorporating personalized remote support with supervision from a neuropsychologist into a digitalized cognitive stimulation program will reinforce the effectiveness of the intervention on cognitive complaints. This will be achieved by improving participation/adherence to the online cognitive stimulation program, as well as through the personalized supervision itself. Investigator believe that the supervision sessions, including educational components, will enable patients to identify their strengths, promote their cognitive awareness, and develop individualized strategies to apply their compensatory abilities in real-life situations. Since cognitive difficulties have multiple underlying causes, reducing these symptoms requires a multifaceted approach. The hypothesis is that combining cognitive training (which increases neuroplasticity and directly targets the cognitive domains affected by cancer and its treatments), with structured supervised educational sessions based on compensatory strategies, will yield better outcomes than online cognitive stimulation alone.
Status | Not yet recruiting |
Enrollment | 300 |
Est. completion date | March 2029 |
Est. primary completion date | June 2028 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Months and older |
Eligibility | Inclusion Criteria: - Patient diagnosed with localized breast cancer - Age 18 or older, - Who have received adjuvant or neo-adjuvant chemotherapy and are currently undergoing adjuvant radiotherapy (ongoing hormone therapy is permitted) until 30 days after end of radiotherapy. - Patients who report cognitive complaints that significantly impact their quality of life, as evaluated by the quality of life subscale of the FACT-Cog questionnaire. This subscale is composed by 4 questions: 1. I have been upset about these problems; 2. These problems have interfered with my ability to work; 3. These problems have interfered with my ability to do things I enjoy; 4. These problems have interfered with the quality of my life. Patients are eligible if their score on this subscale is at or below the 10th percentile, based on age guidelines and normative data (Lange et al., 2015), namely: - = 8 for patients aged 30-49 years - = 9 for patients aged 50-69 years - = 10 for patients aged 70-89 years - Patients who have completed at least three years of primary school education, as determined by the Barbizet scale, - Patient with access to a functional laptop/computer with a keyboard, internet connection and an e-mail account - being able to use those tools alone, - Fluent in French, - Patients who have provided informed consent to participate in the study. Exclusion Criteria: - Personality disorder or any known progressive psychiatric pathology (e.g. schizophrenia), - Previous neurological history with ongoing cognitive symptoms (sequelae of head trauma, stroke, multiple sclerosis, epilepsy, neurodegenerative pathology, etc.), - Excessive alcohol intake or drug use, which could compromise participation to the intervention - Major visual and/or hearing deficit, - Patient who might not be able to complete neuropsychological testing, (including those with significant cognitive disorders that impede the completion of cognition tests, as determined by the cognitive screening test MoCA (MONTREAL COGNITIVE ASSESSMENT) and based on age and educational level according to GRECOGVASC (Reflection Group for Vascular COGnitive Assessment) normative data) - Already participating in a cognitive training program, - Refusal to participate, - Patient deprived of liberty or under guardianship, - Patient who might not be able to participate due to geographic, social or psychopathological reasons. |
Country | Name | City | State |
---|---|---|---|
France | Polyclinique Bordeaux Nord Aquitaine | Bordeaux | |
France | Centre hospitalier de Bligny | Briis-sous-Forges | |
France | Centre François Baclesse | Caen | |
France | Centre George François Leclerc | Dijon | |
France | Groupe Hospitalier Mutualiste de Grenoble | Grenoble | |
France | CHU de Limoges | Limoges | |
France | Centre Léon Bérard | Lyon | |
France | Institut Paoli Calmettes | Marseille | |
France | ICM Val d'Aurelle | Montpellier | |
France | Institut de Cancérologie de Lorraine | Nancy | |
France | Centre Antoine Lacassagne | Nice | |
France | CHU de Nimes | Nimes | |
France | La Pitié Salpétrière | Paris | |
France | Centre Arrmoricain d'Oncologie | Plérin | |
France | Centre Henri Becquerel | Rouen | |
France | Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
Centre Francois Baclesse | UNICANCER |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average change in the score of the Perceived Cognitive Impairment (PCI) subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) | Perceived Cognitive Impairment (PCI) score range 0-72 (The higher the score, the fewer cognitive complaints) | After 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |